Results 191 to 200 of about 2,188,608 (303)

Correction: Signaling pathways and targeted therapy for pulmonary hypertension. [PDF]

Signal Transduct Target Ther
Adu-Amankwaah J, Shi Y, Song H, Ma Y, Liu J, Wang H, Yuan J, Sun K, Hu Q, Tan R.   +9 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Targeting signaling pathways in lymphoma: From molecular mechanisms to clinical breakthroughs. [PDF]

Chin Med J (Engl)
Wang S, Qiu Y, Zhao W.
europepmc   +1 more source

Checkpoint blockade and the stem‐like T cell trade‐off

Molecular Oncology, EarlyView.
Stem‐like T cells are key to the success of programmed cell death protein 1 (PD1) blockade, as they sustain long‐term anti‐tumor response by continuously generating effector CD8+ T cells. However, how these cells are maintained in cancer is not fully understood. Hor et al.
Julie M. Mazet, Johanna A. Joyce
wiley   +1 more source

Aberrant Signaling Pathways in Squamous Cell Lung Carcinoma

Cancer Informatics, 2011
Ivy Shi,, Nooshin Hashemi Sadraei, Zhong-Hui Duan, Ting Shi   +3 more
doaj  

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Unraveling the Impact of KRAS Accessory Proteins on Oncogenic Signaling Pathways. [PDF]

Cells
Garg V, Hofmann RNHM, Saleem M, Mirzaiebadizi A, Hashemi GS, Hameed T, Jooyeh B, Pudewell S, Mehrabipour M, Mosaddeghzadeh N, Piekorz RP, Ahmadian MR.   +11 more
europepmc   +1 more source

DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen, Jiancheng Cheng, Ruili Hou, Xiaoyuan Zheng, Li Su, Maria Moksnes Bjaanæs, Anna Karlsson, Maria Planck, Johan Staaf, Åslaug Helland, Manel Esteller, David C. Christiani, Feng Chen, Xiaofei Cao, Ruyang Zhang   +14 more
wiley   +1 more source

Screening of signaling pathways and hub genes in Guillain-Barré syndrome based on bioinformatics and machine learning. [PDF]

BMC Neurol
Zhang D, Wang Z, Ma W, Wang Z.
europepmc   +1 more source